Aurorus offers a non-invasive, FDA-cleared platform for whole-body health assessment using biophotonic emissions measured via a finger scan. This technology provides comprehensive insights into organ and system health within 15 minutes, eliminating the need for blood draws or radiation.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional health assessments often require invasive procedures like blood draws or expose patients to radiation, limiting their frequency and accessibility. This can delay the identification of organ and system-level health risks and hinder timely therapeutic evaluation.
Solution
Aurorus provides a non-invasive, whole-body health assessment platform that utilizes biophotonic emissions measured via a simple finger scan. This FDA-cleared technology delivers comprehensive insights into organ and system health within 15 minutes, eliminating the need for blood draws or radiation. The platform enables rapid disease identification and supports therapeutic evaluation across various healthcare applications, offering a cost-effective alternative to conventional diagnostic methods.
Target Audience
The primary target audience includes healthcare providers, hospital networks, and organizations involved in drug trials or military evaluations seeking efficient and non-invasive health assessment tools.
Features
- Non-invasive biophotonic emission measurement via finger scan for whole-body health assessment.
- FDA-cleared technology for organ and system health evaluation.
- Rapid assessment completion time of 15 minutes.
- Eliminates the need for blood draws and radiation exposure.
- Measures the electrophysiological status of 49 organs and organ systems.
- Supports applications including wellness assessment, therapeutic evaluation, dosage optimization, and disaster triage.
- Offers a cost-effective solution with an estimated cost per assessment under $100.